摘要
目的:探讨格列美脲与二甲双胍联合使用对于2型糖尿病(T2DM)患者游离脂肪酸(FFA)与胰岛素抵抗(IR)的影响。方法:将84例T2DM患者随机分为格列美脲单用组、二甲双胍单用组以及两者合用组,每组各28例,疗程6个月。比较治疗前后FFA和胰岛素抵抗指数(HOMA-IR)的变化。结果:二甲双胍单用组和两药联用组FFA的水平下降明显,但是格列美脲单用组变化不明显,差异具有统计学意义(P<0.05);而3组的HOMA-IR治疗后虽有所下降,但差异无统计学意义(P>0.05)。结论:格列美脲联用二甲双胍能够降低T2DM的FFA水平,并且能改善HOMA-IR。
Objective： To investgate the effect of glimepiride and metformine on free fatty acid and insulin resistance in patients with type 2 diabetes mellitus. Methods= The levels of FFA and HOMA- IR were compared between glimepiride group and metformine group as well as their combination treatment group before and after six months treatment. Results： The con- centration of FFA didnct significantly change in the glimepiride treated group at the end of treatment, but it obviously decreased in the metformin treated group and in the glimepiride plus metformin treated group （P〈0.05 and P〈0. 001, respec tively）. The levels of fast insulin after six month treatment was higher than before in three groups, But glimepiride group difference was more significant than metformine group and combination group. The levels of HOMA- IR in three groups after six month was lower than before, but there were no significant differences in three groups. Conclusion： Glimepiride and met- lorraine all improve Homa- IR in patients with type 2 diabetics, but glimepiride is better than metformine in treating hyperin- sulina. And they can decrease FFA levels.
出处
《海南医学院学报》
CAS
2015年第3期360-361,365,共3页
Journal of Hainan Medical University
基金
中山市科技局(20102C141)~~
